Orris

Patient profile Age 60 male Known case of t2dm plus autoimmune thyroiditis plus CKD plus hypertension 3 months ago upcr was 242 Put on finrenone 10 od Now UACR is 34

Reading File
Finding Sources
Searching PubMed

finerenone diabetic kidney disease proteinuria reduction

Searching the Web

finerenone 10mg uptitration 20mg UACR response CKD T2DM 2025 guidelines

Reading File
Reading Article

PMID: 38048573

Reading Article

PMID: 40470996

Now I have excellent data to give a thorough clinical interpretation. Let me compile the complete analysis.

Clinical Assessment: Finerenone Response in This Patient

Understanding the Numbers

Parameter3 Months AgoNow
UPCR242 mg/mmol-
UACR-34 mg/mmol
FinerenoneNot on10 mg OD x 3 months
Note on units: UPCR (urine protein:creatinine ratio) and UACR (urine albumin:creatinine ratio) measure different things - albumin is a subset of total protein. A UPCR of 242 mg/mmol roughly corresponds to a UACR in the moderately-severely elevated range (approximately 200-300+ mg/mmol equivalent, depending on the albumin:protein ratio). The current UACR of 34 mg/mmol is in the mildly elevated (A2 borderline) range, nearly at the normal threshold (<30 mg/mmol = normal).
This represents an approximately 86-90% reduction in proteinuria - an exceptional response.

Is This Response Expected?

This is a better-than-average but clinically plausible response. In the FIDELIO-DKD and FIGARO-DKD trials:
  • Finerenone reduced UACR by ~31-32% at Month 4 vs. placebo (prescribing information data)
  • In the ARTS-DN Phase IIb dose-finding study, finerenone 10 mg produced a 25% placebo-corrected UACR reduction at Day 90; 20 mg produced 38%
  • A mediation analysis (Agarwal et al., Ann Intern Med 2023 [PMID 38048573]) showed that a ≥30% UACR reduction was achieved in 53% of finerenone-treated patients vs. 27% placebo, and that early albuminuria reduction mediated 84% of finerenone's kidney-protective effect
This patient's dramatic response likely reflects:
  1. Strong MR-pathway dependence of his proteinuria (inflammatory/fibrotic component)
  2. His autoimmune thyroiditis may have had an additive pro-inflammatory state driving aldosterone-MR activation
  3. Possible concurrent optimization of RAS blockade or BP control over the same period

What to Do Now - Dose Uptitration

Per the FDA-approved prescribing information, the protocol is:
  • Start at 10 mg OD if eGFR 25-59 mL/min/1.73m2 (or 20 mg if eGFR ≥60 + K+ ≤4.8 mmol/L)
  • After 4 weeks, reassess serum potassium and eGFR:
    • If K+ ≤4.8 mmol/L and eGFR has not decreased by >30% from baseline → uptitrate to 20 mg OD (target dose)
    • If K+ 4.8-5.5 mmol/L → maintain at 10 mg
    • If K+ >5.5 mmol/L → hold/stop
This patient has been on 10 mg for 3 months. The key question is: was he ever uptitrated to 20 mg?
If not - and if K+ is ≤4.8 mmol/L now - uptitration to 20 mg should be considered, as 20 mg is the target therapeutic dose. The fact that UACR is already near-normal on 10 mg is very favorable, but the 20 mg dose provides greater organ protection per trial data.

Immediate Action Checklist

Labs to check before uptitration:
  • Serum potassium (must be ≤4.8 mmol/L to uptitrate)
  • eGFR/serum creatinine (uptitrate only if eGFR has not fallen >30% from baseline)
  • If not already done: fasting glucose/HbA1c, thyroid function (TSH/FT4 - autoimmune thyroiditis can cause both hypothyroid and hyperthyroid phases affecting BP and K+)

Optimizing the Broader CKD/T2DM Regimen

Given current 2024-2026 KDIGO guidelines and the CONFIDENCE trial data ([PMID 40470996], NEJM 2025), this patient should ideally be on a four-pillar nephroprotective regimen:
PillarDrug ClassThis Patient
1RAS inhibitor (ACEi or ARB) at max tolerated doseConfirm on board
2SGLT2 inhibitor (empagliflozin/dapagliflozin)Add if eGFR ≥20 and not contraindicated
3Finerenone (nonsteroidal MRA)✓ On board - consider uptitrating to 20 mg
4GLP-1 RA (semaglutide)Consider if weight/CV benefit warranted
The CONFIDENCE trial (Agarwal et al., NEJM 2025) showed that finerenone + empagliflozin together reduced UACR 29-32% more than either agent alone, with no unexpected adverse events. If he is not on an SGLT2i, this is the strongest evidence base for adding one now.

Special Considerations for This Patient

Autoimmune thyroiditis:
  • Hypothyroid state increases aldosterone sensitivity and can worsen fluid retention/hypertension - ensure thyroid is optimally replaced (TSH 0.5-2.5 mIU/L ideal in CKD)
  • Levothyroxine absorption can be affected by timing with other medications
CKD + Hypertension:
  • Target BP <120/80 mmHg per recent KDIGO 2024 update (if tolerated)
  • Finerenone lowers systolic BP by approximately 3 mmHg - modest but additive
Hyperkalemia monitoring:
  • This patient has CKD + is on finerenone + likely on RAS blockade = triple risk for hyperkalemia
  • Recheck K+ at 4 weeks after any dose change, then every 3-4 months thereafter
  • If K+ rises, dietary counseling and consider patiromer/sodium zirconium cyclosilicate as K+-binders

Summary

This patient has had an outstanding proteinuria response to finerenone 10 mg OD - UACR near-normalizing from an elevated baseline. Key next steps:
  1. Check K+ and eGFR - if K+ ≤4.8 mmol/L and eGFR stable, uptitrate finerenone to 20 mg OD (the evidence-based target dose)
  2. Add SGLT2 inhibitor if not already prescribed (empagliflozin 10 mg or dapagliflozin 10 mg) - the CONFIDENCE trial confirms additive benefit on proteinuria and kidney outcomes
  3. Ensure RAS blockade is at maximum tolerated dose (ACEi or ARB)
  4. Monitor thyroid function - optimized replacement in autoimmune thyroiditis reduces cardiometabolic risk
  5. Repeat UACR in 3 months to confirm sustained response at new dose
  6. Monitor for hyperkalemia at every visit - this combination carries real risk
The early, dramatic UACR reduction with finerenone is itself a strong prognostic marker. Per the Agarwal mediation analysis, a ≥30% UACR reduction (this patient has far exceeded that) mediates ~84% of finerenone's kidney-protective effect - meaning this patient is likely deriving the full benefit of the drug.
Evidence base: Comprehensive Clinical Nephrology, 7th Ed. (MRA section) | FIDELIO-DKD/FIGARO-DKD trials | Agarwal et al., Ann Intern Med 2023 [PMID 38048573] | CONFIDENCE trial, NEJM 2025 [PMID 40470996] | Kerendia Prescribing Information (Bayer)

Already on dapagliflozin plus telmisartan 20

Searching PubMed

telmisartan dose CKD diabetic nephropathy maximum tolerated

Searching the Web

telmisartan 20mg vs 40mg vs 80mg CKD proteinuria maximum dose KDIGO 2024

This is very helpful. Now the focus shifts sharply - the patient is on all three pillars but there's one glaring issue. Here's the updated picture:

Updated Clinical Picture

Current regimen:
  • Telmisartan 20 mg OD
  • Dapagliflozin (dose not specified)
  • Finerenone 10 mg OD
The response is excellent - but one issue stands out immediately.

The Problem: Telmisartan 20 mg is a Sub-therapeutic Dose

This is the most important clinical gap in this regimen.
KDIGO 2024 Practice Point 3.6.1 is explicit: "RASi (ACEi or ARB) should be administered using the highest approved dose that is tolerated to achieve the proven benefits, because the proven benefits were achieved in trials using these doses."
Telmisartan dosing in nephroprotection:
  • Starting/low dose: 20 mg
  • Standard dose: 40 mg
  • Maximum nephroprotective/antihypertensive dose: 80 mg OD
The landmark DETAIL and ONTARGET trials, and the Indian retrospective data on UACR reduction, all used telmisartan 40-80 mg. Studies show proteinuria reduction of ~30% with 80 mg vs. lesser reduction at lower doses. At 20 mg, this patient is almost certainly under-dosed on his ARB - which also means finerenone was placed on top of a suboptimal RAS blockade foundation.
Action: Uptitrate telmisartan from 20 mg → 40 mg now, then reassess BP and K+ at 4 weeks; if tolerated, consider 80 mg - provided BP and potassium allow.

Complete Management Plan - Now

Priority 1: Uptitrate Telmisartan

  • Go to 40 mg OD now (can step to 80 mg at next visit if BP/K+ tolerated)
  • Recheck BP, K+, and creatinine at 4 weeks
  • Watch for first-dose hypotension (he's on 3 antihypertensive/nephroprotective agents)

Priority 2: Uptitrate Finerenone to 20 mg

  • 10 mg is the starting dose; 20 mg is the evidence-based target dose
  • Uptitrate only if K+ ≤4.8 mmol/L and eGFR has not fallen >30% from pre-finerenone baseline
  • Do not do both uptitrations simultaneously - stagger them 4 weeks apart to isolate any adverse effects (BP drop, hyperkalemia)

Priority 3: Confirm Dapagliflozin Dose

  • Standard renoprotective dose: dapagliflozin 10 mg OD
  • Works down to eGFR ≥25 mL/min/1.73m2 (DAPA-CKD trial) - confirm current eGFR

Priority 4: Monitoring - This Triple Combination Carries Real Risk

RiskMechanismAction
HyperkalemiaARB + finerenone + CKDK+ at every dose change, then q3 months
HypotensionARB + SGLT2i + finerenone (collective ~8-10 mmHg SBP lowering)Check standing BP; reduce dose if symptomatic
AKISGLT2i + ARB combined in volume depletionSick-day rules: hold both if vomiting/diarrhea/fever
eGFR dipExpected initial eGFR dip with ARB uptitration and SGLT2i (hemodynamic)Do not panic - reassess at 4-6 weeks

The Excellent News: What This UACR Means

UACR 34 mg/mmol on an incompletely optimized regimen (subtherapeutic ARB dose) is remarkable. Once telmisartan is uptitrated to 80 mg and finerenone to 20 mg, this patient may achieve:
  • UACR <30 mg/mmol (complete remission of albuminuria)
  • Stable or improving eGFR trajectory
  • Significant reduction in CV event risk
Per the Agarwal mediation analysis (Ann Intern Med 2023), achieving this degree of albuminuria reduction mediates ~84% of finerenone's kidney-protective effect. This patient is on track for excellent long-term outcomes if the regimen is optimized.

Additional Consideration: Thyroid

  • Autoimmune thyroiditis (likely Hashimoto's) - check TSH. Hypothyroidism worsens:
    • Hypertension (reduced cardiac output, increased vascular resistance)
    • Dyslipidemia (accelerates CKD cardiovascular risk)
    • Hyponatremia and fluid retention (can falsely elevate UACR)
  • Target TSH: 0.5-2.5 mIU/L in this age group

Summary of Next Steps

  1. Uptitrate telmisartan 20 mg → 40 mg (critical gap; max dose target is 80 mg)
  2. Uptitrate finerenone 10 mg → 20 mg at next visit if K+ ≤4.8 mmol/L (stagger 4 weeks from ARB change)
  3. Confirm dapagliflozin 10 mg OD
  4. Check: K+, eGFR, BP, TSH at next visit
  5. Sick-day rules counseling for the SGLT2i + ARB combination
  6. Repeat UACR in 3 months - target <30 mg/mmol
The telmisartan dose is the most immediately actionable gap in an otherwise well-constructed regimen.
This is a shared conversation. Sign in to Orris to start your own chat.